California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts
The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.
View original article
Contributor: Benjamin Ryan
